NZ527173A - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy

Info

Publication number
NZ527173A
NZ527173A NZ527173A NZ52717301A NZ527173A NZ 527173 A NZ527173 A NZ 527173A NZ 527173 A NZ527173 A NZ 527173A NZ 52717301 A NZ52717301 A NZ 52717301A NZ 527173 A NZ527173 A NZ 527173A
Authority
NZ
New Zealand
Prior art keywords
human antibodies
cancer therapy
specific human
selective cancer
chain variable
Prior art date
Application number
NZ527173A
Other languages
English (en)
Inventor
Yocheved Hagai
Janette Lazarovits
Rachel Guy
Orly Lipschitz
Esther Szanthon
Avigdor Levanon
Daniel Plaksin
Tuvia Peretz
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of NZ527173A publication Critical patent/NZ527173A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ527173A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy NZ527173A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
PCT/US2001/049440 WO2002059264A2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Publications (1)

Publication Number Publication Date
NZ527173A true NZ527173A (en) 2006-03-31

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527173A NZ527173A (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (zh)
JP (1) JP2004524023A (zh)
KR (1) KR20030091952A (zh)
CN (1) CN100374456C (zh)
AU (1) AU2002246737B2 (zh)
BR (1) BR0116763A (zh)
CA (1) CA2433227A1 (zh)
CZ (1) CZ20031983A3 (zh)
HU (1) HUP0400775A2 (zh)
IL (1) IL156690A0 (zh)
MX (1) MXPA03005944A (zh)
NZ (1) NZ527173A (zh)
PL (1) PL365758A1 (zh)
RU (1) RU2316564C2 (zh)
WO (1) WO2002059264A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
MX2007013304A (es) 2005-04-26 2007-12-13 Pfizer Anticuerpos de p-caderina.
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
US9211344B2 (en) * 2010-07-09 2015-12-15 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
ES2731876T3 (es) * 2014-10-23 2019-11-19 Singh Molecular Medicine Llc Anticuerpos de dominio sencillo contra antígenos intracelulares
CA2970255A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN114195882A (zh) * 2015-10-01 2022-03-18 圣拉斐尔医院有限公司 Tcr及其用途
AU2016358296B2 (en) * 2015-11-19 2020-05-21 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
DK4050034T3 (da) * 2016-09-14 2024-06-03 Teneoone Inc Cd3-bindende antistoffer
WO2022103961A1 (en) * 2020-11-13 2022-05-19 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.

Also Published As

Publication number Publication date
CZ20031983A3 (cs) 2005-07-13
HUP0400775A2 (en) 2007-05-02
KR20030091952A (ko) 2003-12-03
JP2004524023A (ja) 2004-08-12
AU2002246737B2 (en) 2007-03-01
CN100374456C (zh) 2008-03-12
WO2002059264A2 (en) 2002-08-01
WO2002059264A3 (en) 2003-03-06
IL156690A0 (en) 2004-01-04
EP1353937A2 (en) 2003-10-22
MXPA03005944A (es) 2005-04-29
CN1551886A (zh) 2004-12-01
EP1353937A4 (en) 2005-04-13
BR0116763A (pt) 2004-03-09
PL365758A1 (en) 2005-01-10
RU2003123100A (ru) 2005-03-10
RU2316564C2 (ru) 2008-02-10
CA2433227A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
NZ527173A (en) Specific human antibodies for selective cancer therapy
ATE218890T1 (de) Bispezifische moleküle mit klinischer verwendbarkeit
AU2003278002A1 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
NZ332566A (en) Antigen binding fragments that specifically detect cancer cells
HK1076128A1 (en) Humanized collagen antibodies and related methods
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
EA201100128A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
HK1072272A1 (en) Anti-ccr5 antibody
IL172242A0 (en) Antibodies specific for cancer associated antigen sm5-1 and uses thereof
DE60033455D1 (de) Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
EP1581096A3 (en) Antigen pipa and antibodies that bind thereto
AU6171894A (en) Preparation of photoprotein conjugates and methods of use thereof
AU3587599A (en) Single chain monoclonal antibody fusion reagents that regulate transcript ion in vivo
AU2003226127A1 (en) Antibody libraries
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
WO2004050849A3 (en) Recombinant immunotoxin and use in treating tumors
WO2003066821A3 (en) Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
WO2005070456A8 (en) Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
AU2002245615A1 (en) Method for treating cancer using a33 specific antibodies and chemotherapeutic agents
WO2005049652A3 (en) Methods of generating antibody diversity in vitro
NO20005833D0 (no) Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed